driven by the TFRS 16 – Lease implementation. Company’s financial position was still strong with the D/E ratio including and excluding TFRS 16 – Lease effect of 2.84 and 1.10 times, respectively which it

, while personal expense of the Company increased by only 5% y-y. In terms of proportion to total revenues, operating and administrative expenses represented 42% of total revenues, which is the same level

. In terms of proportion to total revenues, operating and administrative expenses represented 42% of total revenues. Considering the Company’s separate financial statement, the operating and

Rights and Duty of Debenture Issuer and Debenture Holder, the Company is required to maintain the Net Debt to Equity ratio at the rate of not more than 2.5: 1 at the end of the quarter and year end period

selling medical equipment 60.65 73.92 Administrative expenses 109.64 105.99 Finance costs 22.86 24.24 Finance costs (net) 20.87 21.71 Proportion of cost of medical treatment / revenue of medical treatment

590.59 553.11 Cost of selling medical equipment 65.30 57.70 Administrative expenses 112.97 109.49 Finance costs 19.32 24.93 Finance costs (net) 16.90 22.87 Proportion of cost of medical treatment / revenue

Company shall subscribe the newly issued share in proportion of 108,022 shares and the newly issued share in portion of the unsubscribed shares of other shareholders of 40,604 shares. As subscription of

) Proportion of assets acquired (100%) x NTA AT-ZE (29.78) NTA WINNER (604.68) 4.93 % 2. Net income Proportion of assets acquired (100%) x Net income AT-ZE (5.47) Net income WINNER (104.39) 5.24 % 3. Value of

Calculation Method Transaction size 1. Net tangible assets (NTA) Proportion of assets acquired (100%) x NTA AT-ZE (29.78) NTA WINNER (604.68) 4.93 % 2. Net income Proportion of assets acquired (100%) x Net

skin medicine under trademarks including trademark of “DERMALIS”, (which will be Criterion Calculation Method Transaction size 1. Net tangible assets (NTA) Proportion of assets acquired (100%) x NTA AT